Increased matrix metalloproteinases 2 and 9 and tissue inhibitor of matrix metalloproteinase 2 expression is associated with progression from vulvar intraepithelial neoplasia to invasive carcinoma

References

• Fox H, Wells M. Recent advances in the pathology of the vulva. Histopathology. 2003;42:209–16.
   PubMed Web of Science ®Google Scholar
• Scurry J, Wilkinson EJ. Reviwev of terminology of precursors of vulvar squamous cell carcinoma. J Low Genit Trac Dis. 2006;10:161–9.
   PubMedGoogle Scholar
• Rouzier R, Morice P, Haie-Meder C, Lhomme C, Avril MF, Duvillard P, Castaigne D. Prognostic significance of epithelial disorders adjacent to invasive vulvar carcinomas. Gyn Oncol. 2001;81:414–19.
   Google Scholar
• Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T. Regulation of matrixmetalloproteins: an overview. Mol Cell Biochem. 2003;253:269–85.
   PubMed Web of Science ®Google Scholar
• Zucker S, Cao J, Chen WT. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 2000; 72;19:6642–50.
   PubMed Web of Science ®Google Scholar
• Kerkela E, Saarialho-Kere U. Matri metalloproteinases in tumor progression: focus on basal and squamous cell skin cancer. Exp Dermatol. 2003;12:109–25.
   PubMed Web of Science ®Google Scholar
• Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: Biological activity and clinical implications. J Clin Oncol. 2000;18:1135–49.
   PubMed Web of Science ®Google Scholar
• Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. Cancer 1993;71:1260–70.
   Google Scholar
• Jiang Y, Goldber ID, Shi E. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene. 2002;21:2245–52.
   PubMed Web of Science ®Google Scholar
• Bovo AC, Guerreiro da Silva ID, Takita L, Fochi J, Stavale J, Marks G, Lima GR. A comparative study of MMP-2 in vulvar neoplasms. Gyn Oncol. 2004;93:454–7.
   PubMed Web of Science ®Google Scholar
• Höyhtyä M, Fridman R, Komarck D, Porter-Jordan K, Stetler-Stevenson WG, Liotta LA, Immunohistochemical localization of matrix metalloproteinase-2 and its spesific inhibitor TIMP-2 in neoplastic tissue with monoclonal antibodies. Int J Cancer. 1994;54:500–5.
   Google Scholar
• Talvensaari A, Apaja-Sarkkinen M, Höyhtyä M, Westerlund A, Puistola U, Turpeenniemi-Hujanen T. Matrix metalloproteinase 2 immunoreactive protein appears early in cervical epithelial dedifferentiation. Gyn Oncol. 1999;72:306–11.
   Google Scholar
• Da Silva Cardeal LB, Brohem CA, Correa TC, Winnischofer SM, Nakano F, Boccardo E, Higher expression and activity of metelloproteinases in human cervical carcinoma cell lines is associated with HPV precence. Biochem Cell Biol. 2006;84:713–19.
   Google Scholar
• Asha Nair S, Karunagaran D, Nair MB, Sudhakaran PR. Changes in matrix metalloproteinases and their endogenous inhibitors during tumor progression in the uterine cervix. J Cancer Res Clin Oncol. 2003;129:123–31.
   PubMed Web of Science ®Google Scholar
• Brummer O, Böhmer G, Hollwitz B, Flemmig P, Petry KU, Kuhnle H. MMP-1 and MMP-2 in the cervix uteri in different steps of malignant transformation- an immunohistochemical study. Gyn Oncol. 2002;84:222–7.
   PubMed Web of Science ®Google Scholar
• Gaiotto MA, Focchi J, Ribalta JL, Stavale JN, Baracat EC, Lima GR, Guerreiro da Silva ID: Comparative study of MMP-2 (matrix metalloproteinase-2) immune expression in normal uterine cervix, intraepithelial neoplasias and squamous cells cervical carcinoma. Am J Obstet Gynecol. 2004;190:1278–82.
   PubMedGoogle Scholar
• Nasr M, Ayyad SB, El-Lamie IK, Mikhail MY. Expression of matrix metalloproteinase-2 in preinvasive and invasive carcinoma of the uterine cervix. Eur J Gynecol Oncol. 2005;26:199–202.
   PubMedGoogle Scholar
• Branca M, Ciotti M, Giorgi C, Santini D, Di Bonito L, Costa S, ; HPV-PathogenISS Study Group. Matrix metalloproteinase-2 (MMP-2) and its tissue inhibitor (TIMP-2) are prognostic factors in cervical cancer, related to invasive disease but not high-risk human papillomavirus (HPV) or virus persistance after treatment of CIN. Anticancer Res. 2006:1543–56.
   Google Scholar
• Davidson B, Goldberg J, Kopolovic L, Lerner-Geva L, Gotlieb WH, Weis B, Expression of matrix metalloproteinase-9 in squamous cell carcinoma of the uterine cervix- clicopathologic study using immunohistochemistry and mRNA in situ hybridization. Gyn Oncol. 1999;72:380–6.
   Google Scholar
• Shimada T, Nakamura H, Yamashita K, Kawata R, Murakami Y, Fujimoto N, Enhancd production and activation of progelatinases A mediated by membrane-type 1 matrix metalloproteinase in human oral squamous cell carcinoma: implications for lymph node metastasis. Clin Exp Metast. 2000:18:179–88.
   Google Scholar
• De Vicente JC, Fresno MF, Villain L, Vega JA, Lopez Arranz JS. Immunoexpression and prognostic significance of TIMP-1 and -2 in oral squamous cell carcinoma. Oral Oncol. 2005:41;568–79.
   Google Scholar
• Christopoulos TA, Papageorgakopoulos N, Ravazoula P, Masrtonikolis NS, Papados TA, Theocharis DA, Expression of matrix metalloproteimases and their inhibitors in squamous cell laryngeal carcinoma. Oncol Rep. 2007;18:855–60.
   PubMed Web of Science ®Google Scholar
• Aglund K, Rauvala M, Puistola U, Angstrom T, Turpeenniemi-Hujanen T, Zackrisson B, Gelatinases A and B (MMP-2 and MMP-9) in endometrial cancer- MMP-9 correlates to the grade and stage. Gyn Oncol. 2004;94:699–704.
   PubMedGoogle Scholar
• Graesslin O, Cortez A, Fauvet R, Lorenzato M, Birembaut P, Darai E. Metalloproteinase-2, -7 and -9 and tissue inhibitor of metalloproteinase-1 and -2 expression in normal, hyperplastic and neoplastic endometrium: a clinical-pathological correlation study. Ann Oncol. 2006;17:637–45.
   PubMed Web of Science ®Google Scholar
• Honkavuori M, Talvensaari-Mattila A, Soini Y, Turpeenniemi-Hujanen T, Santala M. MMP-2 expression associates with CA 125 and clinical course in endometrial carcinoma. Gyn Oncol 2007;104:217–21.
   PubMedGoogle Scholar
• Maatta M, Santala M, Soini Y, Talvensaari A, Turpeenniemi-Hujanen T. Matrix metalloproteinases 2 and 9 and their tissue inhibitors in low maliganat potential ovarian tumors. Tumor Biol. 2004;25:188–92.
   PubMed Web of Science ®Google Scholar